uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - uniQure reported a quarterly loss of $1.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.85, marking a 62.35% earnings surprise [1] - The company's revenues for the quarter were $3.7 million, missing the Zacks Consensus Estimate by 46.62%, but showing an increase from $2.29 million a year ago [2] - The stock has gained approximately 57.4% year-to-date, outperforming the S&P 500's gain of 14.4% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.40 on revenues of $40.73 million, and for the current fiscal year, it is -$3.12 on revenues of $39.82 million [7] Market Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call [3] - The Zacks Rank for uniQure is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Medical - Biomedical and Genetics industry is currently in the top 36% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]